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The morbidity and societal burden of youth bipolar spectrum disorders (BSD) are high. 
These disorders are multisystemic in that adult populations there are clear interactions 
with inflammatory processes and steroidal physiological systems. There are much less 
data concerning these areas of study in youth populations with BSD. This is surprising 
given the association of youth-onset BSD with puberty and its associated physio-
logical changes. In this mini-review, we overview the theoretical role of inflammatory 
processes and steroidal physiological systems in youth BSD, describe the greater 
literature in adult populations, detail the literature in youth populations when available, 
and overview current proposed molecular mechanistic pathways and interaction 
effects based on the available data. We also attend to the interplay of this complex 
system with body composition and weight gain, an especially important consideration 
in relation to the role of second generation antipsychotics as the first line treatment 
for youth with BSD in major clinical guidelines. A developmental model of early onset 
BSD for boys is hypothesized with pubertal hormonal changes increasing risk for first 
(hypo-)manic/depressive episode. The dramatic androgen rise during puberty might 
be relevant for first onset of BSD in boys. A shift from general hypercortisolism driven 
by glucocorticoid resistance to hypocortisolism with further disease progression 
is assumed, while increased levels of inflammation are functionally associated with 
endocrine dysregulation. The interacting role of overweight body habitus and obesity 
in youth with BSD further indicates leptin resistance to be a central moderator of the 
dynamic neurobiology of BSD in youth. The intent of this mini-review is to advance our 
knowledge of youth BSD as multisystemic disorders with important contributions from 
endocrinology and immunology based on a developmental perspective. This knowl-
edge can influence current clinical care and more importantly inform future research.
Keywords: bipolar spectrum disorders, youth, second-generation antipsychotics, obesity, steroid hormones, 
pro-inflammatory cytokines, longitudinal monitoring, big data
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inTRODUCTiOn
Bipolar spectrum disorders (BSDs) are chronic, progressive, and 
multisystemic disorders that are a leading cause of disability 
worldwide (1). BSDs are characterized by their (hypo-)manic 
and depressive episodes and include bipolar I, bipolar II, as well 
as subthreshold bipolar disorders, which represent milder but 
clinically significant syndromes (2). BSD affects up to 6% of the 
general population, and when subthreshold BSD symptoms are 
considered, the societal burden is very high (3). For youth, preva-
lence rates of up to 5% have been reported. Early onset of BSD 
is associated with delayed diagnosis, delayed therapy initiation, 
and an overall more severe clinical outcome (1, 4, 5).
There is a peak age of onset for BSD in adolescence at puberty 
(6–9) suggesting the wisdom of investigation for any causal 
link between puberty-related changes in steroid hormone 
concentrations and BSD development (6–9). In adults, BSDs 
have been shown to be associated with altered steroid hormone 
concentrations (androgens and glucocorticoids) (10–13); yet, 
notably, no studies have investigated the relationship between 
puberty-related changes in steroid secretion and BSDs. In both 
youth and asdults, BSDs do show increased levels of inflamma-
tory markers (14–16), though there remains no studies, which 
explore inflammatory interaction effects with other physiological 
systems including the hypothalamus–pituitary–adrenal (HPA) 
axis and the hypothalamus–pituitary–gonadal axis. This is poten-
tially problematic if we aim to increase our biologic knowledge 
of this multisystemic disorder (17). Thus, in this mini-review, we 
will outline the importance of the study of steroid hormones in 
combination with inflammatory cytokines in BSD with a focus 
on male youth.
Bipolar spectrum disorders-related dysregulations of inflam-
matory processes and steroid secretion might be regarded as 
preceeding conditions predisposing individuals to BSD, or as the 
allostatic load representing the cumulative, multisystemic toll 
of the disease process. In our consideration, we will also outline 
that the use of second generation antipsychotics (SGAs) in youth 
with BSD, which is still considered the first line treatment for 
BSDs, influences both steroid hormone secretion and inflamma-
tion. Weight gain and worsening body composition due to SGA 
treatment might further increase steroid secretion dysregulation 
and inflammatory processes in youth with BSDs and thus play an 
important role in BSD course and progression.
SeARCH STRATeGY
Initial computerized literature search was conducted in PubMed. 
The literature search was conducted using the MeSH terms 
“bipolar disorder,” “mood disorder,” “manic disorder,” “mania,” 
and the modifiers “youth,” “treatment,” “antipsychotics,” 
“inflammation,” “CRP,” “IL-6,” “NF-kB,” “steroids,” “cortisol,” 
“glucocorticoids,” “sex steroids,” “testosterone,” “androgens,” 
“estradiol,” “body composition,” “frailty,” “muscle mass,” or “fat 
mass,” The original PubMed search was conducted for references 
published between January 1, 1950 and February 15, 2017. We 
additionally searched references of selected studies, reviews, and 
meta-analyses for further references. To update the literature 
search, search was repeated on May 15, 2017 and additional 
databases (Medline and Embase) were searched with the above 
listed search terms.
BSD AnD inFLAMMATORY MARKeRS
The immune hypothesis of BSDs postulates that increased immune 
activation precipitates manic and depressive episodes via multiple 
physiologic pathways (18). BSDs are associated with increased 
levels of proinflammatory cytokines in adult populations (14–16). 
A recent meta-analysis concluded that in acutely ill patients 
with bipolar mania interleukin-6 (IL-6), tumor necrosis factor-α 
(TNF-α), soluble interleukin-2 receptor (sIL-2R), and interleukin-
1-receptor-antagonist (IL-1RA) are elevated, while a reduction 
has been identified after BSD treatment for IL-1RA, which is 
thought to reflect interleukin-1 (IL-1) activity (19). For chronically 
ill BSD patients IL-6, interleukin-1β (IL-1β), and sIL-2R (acting 
as counter-regulatory agent) levels were increased in euthymic 
phases (19). Another recently published meta-analysis concern-
ing C-reactive protein (CRP) in different mood states (mania, 
depression, euthymia vs. healthy controls) in BSD patients found 
moderately increased CRP levels for BSD patients in euthymic 
and depressed states, substantially increased CRP levels during 
mania, and a reduction of CRP levels in BSD patients achieving 
euthymia after treatment (20). Interestingly, patients who were not 
taking medication (SGA and others) had significantly higher CRP 
levels in manic and depressive states relative to those who were. 
Supporting evidence for the inflammatory hypothesis also stems 
from a large Mendelian randomization analysis using a genetic 
risk score including four single nucleotide polymorphisms in the 
CRP gene (21). The study showed a 1.21-fold increased risk for 
bipolar disorder with a 10% increase in genetically determined 
CRP levels. Anti-inflammatory agents as putative pharmacologi-
cal intervention against BSD are currently under study, though 
clear evidence for effectiveness is still lacking (22).
Only one study was identified that explored inflammatory 
markers in adolescents (23). In this study, IL-6 and high sensi-
tivity C-reactive protein (hsCRP) were explored. Only hsCRP 
was significantly associated with manic symptom severity (23). 
The lack of studies in children and adolescents is possibly due 
to the difficult access to this very high burdened and vulnerable 
population. To better understand this disorder and to improve 
treatments, more research is needed to clarify the causal relation-
ship of increased inflammation and BSD in youth and only large 
prospective studies might answer this question.
A potential molecular pathway explaining these findings and 
through which inflammation may relate to BSD is the character-
istic of CRP in high peripheral concentrations to increase perme-
ability of the blood–brain barrier and thus by entering the central 
nervous system (CNS) directly to interact with specific CNS 
cells. CRP is thought to cause hyper-reactivity of microglia and 
astrocytes. This reactivity leads to intensified immune activation 
by releasing IL-6 and interferone-γ, activating the tryptotphan 
degrading enzyme indoleamine 2,3-dioxygenase, increasing 
quinolic acid synthesis and 3-hydroxy kynurenine. These gener-
ate oxidative radicals and decrease brain-derived neurotrophic 
factor, contributing to neuronal damage (20, 24).
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Another possible pathway is the NF-kB signaling pathway, 
which is commonly activated in inflammatory or autoimmune 
diseases. This pathway consists of different inducible transcrip-
tion factors that regulate immune and inflammatory responses. 
Chronic cellular stress might dysregulate the NF-kB cascade 
by prolonged activation and subsequent exhaustion and 
hindering it from its primary function—cell protection from 
undergoing apoptosis in response to cellular stress (25, 26). 
The recurrence of mood episodes may induce excessive 
production of proinflammatory cytokines that exceeds the 
downregulatory capacity of the inflammatory system and leads 
to a constant overactivation of microglial cells. Overactivation 
would promote the secretion of proinflammatory cytokines 
such as TNF-α and IL-1β, which might directly drive neuronal 
cell death (27, 28). Supporting findings have been recently 
reported, showing that regulatory factors of the immunoreac-
tion (IL-23, IL-17, TGF-1β, and TNF-α), have been decreased 
after 8  weeks of combination pharmacotherapy with lithium 
and quetiapine in adult bipolar patients achieving response 
(29). These proinflammatory cytokines have been shown to 
mediate cell immunity, humoral immunity, and autoimmun-
ity. However, NF-kB has recently received increased attention 
because of its colocalization in neurons and glial cells and its 
activation during the induction of long-term potentiation—a 
paradigm of synaptic plasticity (30). Therefore, NF-kB signal-
ing seems also to be implicated in controlling of axon initiation, 
elongation, guidance, and dendritic spine density contrasting 
the abovementioned properties and indicating its important 
role in learning, memory, and mental diseases due to the 
modification of neural processes (31).
The presented literature indicates inflammation to be 
bidirectionally involved in BSD development and progression. 
Inflammation has further been closely linked to stress and its 
neuroendocrinology. To what extent steroids are involved in the 
relationship between inflammation and BSD and whether steroid 
hormones independently might contribute to BSD development 
and progression will be outlined in the following.
BSD AnD STeROiD SeCReTiOn
Changes in steroid hormone concentrations have been linked to 
depression outside the BSD population (32–35), and BSDs are 
directly associated with altered steroid hormone concentrations 
(e.g., androgens or glucocorticoids) as well (10–13). For exam-
ple, postmortem brain tissue analysis reveals differing levels of 
neuroactive steroids between patients with BSD and healthy 
controls, suggesting that steroid hormones may be candidate 
modulators of the pathophysiology of the BSDs and potentially 
therapeutically relevant (36). More precisely, pregnenolone, 
which is a progestagen directly metabolized from cholesterol, and 
dehydroepiandrosterone a subsequently metabolized androgen, 
were significantly higher in the posterior cingulate and the pari-
etal cortex of patients with bipolar disorder compared to controls. 
These neuroactive steroids demonstrate physiological relevant 
concentrations and act on the inhibitory GABAA and excitatory 
NMDA receptors. Whether steroids are candidate modulators of 
the pathophysiology of BSDs and which steroids are increased 
or decreased in youth suffering from BSDs is a matter of current 
debate.
Hypothalamus–pituitary–adrenal axis dysregulation and 
altered glucocorticoid function in BSD were reported by Evans 
and Nemeroff 30 years ago (13, 37). Since this initial investigation 
dysfunction at multiple levels of the axis has been discovered. 
Serum cortisol day profiles are elevated in BSD patients over 
all disease phases including mania/hypomania, depression, and 
remission as compared to healthy controls (38). Higher chronic 
cortisol secretion is significantly higher in BSD patients and 
correlated with manic symptoms (11). Higher free urine and 
cerebrospinal fluid cortisol levels are found during mania, 
and many patients with BSDs have attenuated responses to 
the dexamethasone suppression test (DST) (39). Attenuated 
responses indicate a dysregulation of the HPA negative feedback 
and glucocorticoid resistance (40). An increased response to the 
dexamethasone–corticotropin-releasing hormone test (DEX-
CRH) has been reported for acute manic patients compared 
to healthy controls in another rather small sample (41), as well 
as for DST only comparing 24 euthymic BSD patients with 26 
healthy controls. Studies exploring a more differentiated pattern 
of HPA axis dysregulation in BSD have found female sex and age 
of onset to be moderators of DST response, demonstrating the 
importance of sex and developmental differences (42). Age was 
negatively associated with DST response in BSD although cortisol 
is known to continuously increase with age in healthy subjects 
(33, 43), and long-term use of lithium reduced this association, 
suggesting that older age is associated with lower HPA activity in 
BSD. The authors of this study proposed a developmental model 
of HPA activity in BSD suggesting high stress load in BSD over 
time would lead to a progression of the HPA axis regulatory status 
from hypercortisolism and eucortisolism to hypocortisolism. 
Passos and colleagues point out the anti-inflammatory character 
of cortisol based on the glucocorticoid receptor (GR) (27). The 
GR inhibits the NF-kB cascade, which further decreases synthesis 
of proinflammatory cytokines. Therefore, in BSD-induced glu-
cocorticoid resistance (decreased GR function), both elevated 
cortisol and inflammation levels are present due to the loss of the 
anti-inflammaotry properties of the GR (27).
Androgens are present in men up to 10 times higher as in 
women. The aforementioned differences in BSD with regard 
to sex might originate from influences of sex steroids on BSD 
development and progression. Changes in sex steroids have 
also been linked to depression (32–34, 44, 45). Different studies 
show altered androgen levels (e.g., testosterone or dehydroepi-
androsterone) in BSD. Testosterone positively correlates with 
the number of manic episodes and the number of suicides 
when controlled for sex (10), while dehydroepiandrosterone 
levels are elevated in bipolar patients (36). The hypothesis has 
been postulated that low testosterone might be associated with 
psychopathological manifestations such as suicidal behavior in 
older men, while high testosterone levels might be related to 
suicidal behavior in adolescents (46). Peak age of onset for BSD is 
adolescence, suggesting a putative causal link between puberty-
related development changes and vulnerability for BSD develop-
ment (47). Sex-specific endocrine changes are a key determinant 
for this transition phase, which occurs in boys between 8 and 
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17 years of age (48–50). Boys experience a high velocity increase 
of both testosterone and estradiol while girls experience a high 
velocity increase in estradiol and the testosterone precursor 
androstenedione (51). However, other lines of research focused 
on sexually dimorphic fear and aggressive behavior in mice 
regulated by the biosynthesis of neurosteroids (52, 53). Mice 
receiving long-term treatment with anabolic androgenic steroids 
[e.g., testosterone propionate (TP)] showed increased anxiety and 
aggressive behavior (54). In men, long-term treatment with TP 
was associated with impulsive aggression, episodic mania, and 
major depression, while withdrawal was associated with depres-
sive symptoms and suicide attempts indicating sexually different 
effects of sex steroids (54).
As potential pathophysiology underlying mood disorders, sex 
steroids have been shown to affect synthesis, metabolism, recep-
tor concentration, and trafficking of various neurotransmitter 
systems strongly related to mood disorders (44). With regard to 
estradiol, mixed effects are reported for the serotonin and dopa-
mine system. Estradiol has been shown to reduce serotonin trans-
porter (SERT) mRNA transcription as well as alter the peripheral 
SERT protein levels and binding and increase serotonin (5-HT2A) 
receptor binding and mRNA (44). Importantly, 5-HT2A activation 
has been associated with depressive-like phenotypes in a multi-
tude of studies, while 5-HT2A antagonists such as MDL100907 
reduce depressive-like behavior (55). Some inconclusive evidence 
exists that show associations between estradiol, dopamine release, 
and receptor density in specific brain regions (44). However, these 
reviews (44, 56, 57) neglect androgen or testosterone action and, 
not surprisingly, conclude that changes in estradiol levels are 
associated with mood disturbances. In rodent models, estradiol 
seems to mediate the antidepressant-like effects of testosterone 
via aromatization of testosterone to estradiol in the dentate gyrus 
(35). Importantly, serotonergic neurons are only indirectly sensi-
tive to testosterone as they express no androgen receptors (58) 
and are thus influenced through testosterone aromatization to 
estradiol and activation of the estrogen beta receptor.
In humans, a negative association between peripheral 
testosterone—but not estradiol—and global 5-HT4 receptor 
binding has recently been shown for the male brain in 41 healthy 
men using positron emission tomography (59). Perfalk and col-
leagues remark that men and women differ for several aspects 
of the serotonin system as women demonstrate lower 5-HT4 
receptor binding throughout different parts of the limbic system. 
Global 5-HT4 receptor binding is inversely related to synaptic 
serotonin levels, indicating increased extracellular transmitter 
levels to decrease receptor expression and vice  versa (59). Post 
hoc regional analysis of the data demonstrated that there was a 
negative association between peripheral testosterone and 5-HT4 
receptor binding within the hippocampus, while estradiol was 
positively associated only in post hoc analysis to 5-HT4 receptor 
binding within the amygdala (59). As anatomical differences exist 
in individuals with BSD in the amygdala and, in adolescents, 
hippocampal volume, these results seem relevant when con-
structing an informed developmental model (13). Finally, 
testosterone and estradiol are discussed to influence adult 
hippocampal neurogenesis and related antidepressant effects 
attributed to these specific brain areas (60).
Taken together, the reviewed literature shows a considerable 
amount of studies indicating a bidirectional link between steroid 
secretion and BSDs with elevated levels of glucocorticoids and 
androgens in BSDs at an early stage, while there might be a poten-
tial switch to hypo-cortisolism and hypo-gonadism with disease 
progression into older age. However, the underlying pathophysi-
ology is not yet fully understood. Increasing interest has recently 
been paid to developmental models and the organizational effects 
of steroid hormone secretion and inflammatory processes on the 
neurodevelopment with regard to BSDs, what will be discussed 
in the following.
inFLUenCe OF SeX, STeROiDS,  
AnD inFLAMMATORY PROCeSSeS  
On neURODeveLOPMenT
While both sexes undergoe a similar pattern of brain development 
from caudal to rostral and subcortical to cortical-limbic matu-
ration, male fetuses show a slower brain maturation compared 
to females going along with a slower behavioral development 
what is expressed immediately after birth (61, 62). Therefore, 
Schore (63) concludes that the male and female brain display 
differential sensitivity to early life stress. This may account for 
why boys are more susceptible to a number of psychiatric disor-
ders, including autism spectrum disorders and attention-deficit 
hyperactivity disorder. This is supported by research showing for 
example male newborns being less responsive to auditory and 
social stimuli and that male newborns are less able to maintain 
eye contact and show greater difficulties to maintain affective 
regulation (64). Sex steroids have been shown to play a crucial 
role in brain development and organization (65). The slower 
male brain maturation and the greater disinhibition observed in 
boys has been attributed to prenatal testosterone exposure (66). 
However, steroids have multiple functions in different brain 
regions, and androgens and estrogens often display opposing 
effects (60). For androgens, effects such as facilitation of fetal 
synaptogenesis and inhibition of synapse elimination leading to 
slower synaptic maturation as well as influencing of adult hip-
pocampal neurogenesis have been reported (60, 63).
For higher levels of glucocorticoids, detrimental effects on 
the fetal brain development have consistently been reported 
(67), while for microglia, the macrophages of the brain, a major 
role in synaptic pruning during postnatal development has been 
reported linking microglia surveillance to synaptic maturation. 
However, neuroinflammation represented by microglial activa-
tion is strongly determined by psychosocial stress and chronic 
elevated stress with subsequent elevated levels of cortisol induc-
ing excessive microglial activation, what might predispose the 
adolescent brain to BSDs (68).
It is, therefore, well recognized that the developing brain is 
very sensitive to the effects of circulating steroid hormones and 
inflammatory markers during sensitive periods of pre-, peri-, 
and postnatal development, and hormonal surges during critical 
developmental time windows program behavior and physiology 
(e.g., testosterone surge in male fetuses during the 8th to 24th 
week of gestation and again in the first months after birth) (63, 
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69–72). In addition to the effects of steroids and inflammatory 
processes on the neurodevelopmental predispostion to BSDs, the 
pharmacological treatment of BSDs in youth is another relevant 
contributor to inflammatory and steroidal alterations via the 
subsequent weight gain as discussed in the following.
BSD TReATMenT in YOUTH: SGAs ARe 
COnSiDeReD FiRST Line TReATMenT
Since the year 2000, prescription and use of SGAs such as que-
tiapine or olanzapine have risen in adults and in youth (73). SGA 
use is now the first-line treatment for youth with BSDs and has 
given clinical benefits in psychiatric stabilization (74). However, 
this practice is associated with substantial weight gain: at present, 
approximately 70% of youth treated with SGAs are overweight.
Mechanisms of SGA-related weight gain are considered 
multifactorial and include endocrine and metabolic factors. 
Monitoring steroid hormones and specific measures of body 
composition might be of additional interest to further explore 
the causality of SGA-induced weight gain (75, 76). SGAs are 
generally thought to be anti-inflammatory (77), and interesting 
cross-sectional interactions of SGA use, BMI, hsCRP, and glu-
cose levels have been reported (78). Another longitudinal study 
investigating a 6-week SGA (clozapine) treatment in psychotic 
children identified a significant SGA-related increase of a food 
intake stimulating hormone leptin, raising the question of SGA-
induced leptin resistance (76). In a prospective community, cohort 
study of 339 adults followed over 6 months, a weight gain was 
observed in 50% of the adults, while food cravings and chronic 
stress decreased (79). Higher serum cortisol, insulin, and chronic 
stress were independently predictive of greater future weight 
gain again indicating leptin resistance as relevant mechanism in 
BSD progression.
Hypothalamus–pituitary–adrenal axis activation with sub-
sequent glucocorticoid release is thought to increase the intake 
of highly palatable foods (80). A recent study including 2,557 
adults found higher hair cortisol concentrations to be associated 
with higher BMI, waist-circumference, and obesity (81). Chronic 
stress, as represented in elevated hair cortisol concentrations, is 
supposed to cause a disruption of the lipid synthesis leading to 
accumulation of triglycerides in the liver or adipocyte enlarge-
ment. This suggests increased adipocyte proliferation, increases 
hypothalamic expression of NPY, and finally leading to leptin 
resistance (82, 83).
Although different strategies to reduce SGA-related weight 
gain such as healthy lifestyle interventions, switching to lower risk 
antipsychotics, or combination treatment with weight reducing 
medication exist, they show limited effectiveness represented by 
an average weight reduction of around only 3 kg (84). However, 
metformin—known for its prevention of weight gain and its 
extreme safety in youth—emerges as potent adjunct for combina-
tion treatment with SGAs in youth with BSD (85, 86). Metformin 
has already been associated with a statistically and clinically 
significant weight reduction induced by the reduction of hepatic 
gluconeogenesis and the improvement of glucose uptake as well 
as its weight stabilizing capacity (87).
Metformin has further been shown to reduce measures of 
adiposity among overweight and obese adolescents with type 1 
diabetes (88), to inhibit androgen biosynthesis (89, 90), and to 
reduce inflammatory markers such as hsCRP and IL-6 (91–93). 
The anti-inflammatory medication Celecoxib may also be a 
promising adjunct as it has been found to promote an acceler-
ated treatment response among acutely ill patients at early illness 
phase (18). Furthermore, celecoxib has been shown to enhance 
GR function countering glucocorticoid resistance due to GR 
dysfunction in BSD as described above (94). Since weight gain has 
shown to influence BSD progression, a review on the association 
between body composition and mood disorders will subsequently 
be presented.
BODY COMPOSiTiOn AnD MOOD 
DiSORDeRS
Youth with BSD typically show high rates of overweight (BMI 
over 25) and obesity (BMI over 30) (95, 96). Overweight and 
obese youth with BSD display a worse illness course, a higher 
risk of adult overweight/obesity, and higher overall morbidity 
(18, 97).
The treatment of youth with BSD, as above noted to be over-
whelmingly and increasingly with SGAs, is one contribution to 
this state. However, changes in puberty are also contributory. 
In puberty, significant changes in body composition occur and 
need to be taken into account for the longitudinal examination 
of youth with BSD (48). A positive association between fat mass 
and depressive symptoms exists (98, 99). Among many pathways, 
depressive symptoms may cause lipid dysregulation resulting in 
increased fat accumulation (82). Extracellular water (ECW) has 
positive associations with clinical conditions (100), and a recent 
study linked water intake and mood states in healthy young 
women (101). There is only one further study demonstrating 
an association between ECW or water balance and depressive 
symptoms in men (102), while the examination of the relation-
ship of (hypo-)manic symptoms and body water has never been 
carried out.
Obesity has been postulated to be an inflammatory state. 
High levels of inflammatory cytokines have been detected in 
fat cells, and inflammatory cytokines are also involved in the 
fat metabolism and are positively associated with obesity (103). 
Besides HPA axis dysfunction and leptin resistance, adipocyte 
dysfunction is also suggested as an underlying mechanism of 
obesity-associated inflammation (104). Declining adipose tissue 
levels reduce adipose tissue production of TNF-α, IL-6, IL-8, 
and leptin (105). Importantly, adipose tissue also serves as the 
main site of the conversion of testosterone to estradiol. In men, 
around 80% of estradiol is produced in the adipose tissue via 
aromatization (106). Higher testosterone levels are associated 
with better male body composition (more lean mass, less fat 
mass) (107), which are also enhanced by testosterone treatment 
in men (108). Furthermore, as described above, BSDs have 
been related to a dysregulation of the NF-kB signaling pathway 
due to prolonged activation. Increased NF-kB signaling leads 
to increased RANK ligand-induced osteoclastogenesis (109), 
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what might culminate in premature osteoporosis in youth 
suffering from BSDs. In line with this, Bolton and colleagues 
showed that mental disorders and related medication use 
(e.g., antipsychotics, lithium, mood stabilizers) were associated 
with an increased risk for osteoporosis and fractures in adults 
(110). This functional cross talk between male body composition, 
frailty, inflammatory markers, and steroid hormones should be 
taken into account, when deciding on treatment strategies in 
male youth with BSD.
FUTURe DiReCTiOnS AnD COnCLUSiOn
Research on BSD development, progression, and treatment has 
strongly focused on inflammatory markers. Steroid hormones 
and the regulatory mechanisms of body composition itself have 
not yet been sufficiently addressed. The relationship between 
BSD symptomatology, steroid hormones, and inflammatory 
markers has mostly been examined in adult samples. Studies 
investigating the role of changes in steroid hormones, inflam-
matory markers, and body composition in youth with BSD have 
never been carried out.
Large prospective studies need to address this open question 
and should explore interaction effects for this multisystemic 
disorder (17). A recent review suggests that there may be merit 
in attempting to combine different biomarkers for better char-
acterization, prevention, and treatment of BSD (111). We agree 
and in this mini-review have expanded the number of suggested 
biological systems critical to investigate. However, as a major 
limitation of this review on BSDs in youth, it is to mention that 
there are relatively few existing studies, which examined youth 
with BSDs and inflammatory or steroidal markers. Therefore, this 
review was complemented with studies on adult BSDs samples 
reporting levels of inflammatory markers and steroid hormones. 
Conclusions drawn from these studies might, therefore, not be 
entirely applicable to youth populations suffering from BSDs. 
More research on youth suffering from BSD is needed.
Whether dysregulations in the secretion of steroid hormones 
or inflammatory markers represent predisposing factors increas-
ing vulnerability to BSDs in youth, or if these dysregulations are 
to be considered measures of allostatic load emerging due to the 
adaptation to BSDs can only be answered with prospective cohort 
studies monitoring large samples of children. The insights provided 
by these suggested study designs will increase the recognition of 
the relevance of multiple body systems for BSD development, 
progression, and treatment. Monitoring alterations in steroid 
secretion and levels of pro-inflammatory cytokines in youth at 
risk for BSD development presents itself as a promising avenue 
to better understand the dynamic nature of BSD. Moreover, the 
information obtained in these studies will help to counterbalance 
hormonal and inflammatory dysregulations in youth related to 
BSD and promote tailored BSD treatment in youth.
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